About The Study:
Gastroesophageal reflux disease is when stomach acid or bile flows into the food pipe and irritates the food pipe lining. If treated it can remain under control but if left untreated the disease can worsen, leading to very poor digestive health. Heartburn is the main symptom felt but others include belching, nausea, regurgitation, bitter taste, discomfort in the abdomen, and dry cough. GERD can also end up leading to a persistent cough, laryngitis, problems sleeping, and asthma. There are risk factors when experiencing GERD at a young age, and doctors believe that children could have inherited this disease from their parents. Some treatment options include taking antacids, getting a proton-pump inhibitor, and antidiarrheal meds. The study that Rochester Clinical Research is conducting is testing a tegoprazan oral pill that is taken daily for either 4 weeks or 20 weeks. Tegaprazan is a potassium-competitive acid blocker that is used to treat gastroesophageal diseases. The study is for people 18 years old and older and is about 28 weeks long. It is a phase 3 form of treatment that is getting close to getting FDA-approved.
Study-related care is available to participants at no cost and health insurance is not required nor needed. Compensation is also available for your time and travel to participate.
- 18+ years old
- Have experienced heartburn (burning sensation, pain at posterior bony thorax) for at least 6 months
- Have documented history of symptomatic GERD
- Have no mucosal breaks on the upper GI endoscopy
- *Please note, that other conditions may apply